Get the Stockscreener App
0.4066
2.73%
-0.0114
After Hours:
.42
0.0134
+3.30%
Intensity Therapeutics Inc stock is traded at $0.4066, with a volume of 345.33K.
It is down -2.73% in the last 24 hours and down -3.47% over the past month.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
See More
Previous Close:
$0.418
Open:
$0.4077
24h Volume:
345.33K
Relative Volume:
0.01
Market Cap:
$24.42M
Revenue:
-
Net Income/Loss:
$-16.26M
P/E Ratio:
-0.3442
EPS:
-1.1814
Net Cash Flow:
$-13.50M
1W Performance:
-3.17%
1M Performance:
-3.47%
6M Performance:
+35.53%
1Y Performance:
-78.89%
1-Day Range:
$0.4011
$0.4172
1-Week Range:
$0.3672
$0.433
52-Week Range:
$0.1853
$3.1663
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
0.4066 | 25.11M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Intensity Therapeutics Inc Stock (INTS) Latest News
Why Intensity Therapeutics Inc. stock appeals to analystsJuly 2025 Sentiment & Daily Profit Maximizing Tips - Улправда
Why Intensity Therapeutics Inc. stock is a must watch in 2025July 2025 Analyst Calls & Weekly High Conviction Ideas - Улправда
Why Intensity Therapeutics Inc. stock is rated strong buyWeekly Stock Summary & AI Enhanced Trade Execution Alerts - DonanımHaber
Can Intensity Therapeutics Inc. stock double in next 5 years2025 Fundamental Recap & Weekly Breakout Watchlists - Улправда
CEO Change: Can Intensity Therapeutics Inc. stock attract ESG capital inflows2025 Risk Factors & Precise Buy Zone Identification - moha.gov.vn
How Intensity Therapeutics Inc. stock performs in high volatility marketsJuly 2025 Big Picture & Real-Time Stock Entry Alerts - Улправда
Can Intensity Therapeutics Inc. stock rebound after recent weaknessWeekly Volume Report & Risk Managed Investment Signals - DonanımHaber
Portfolio Shifts: Will Intensity Therapeutics Inc. stock split attract more investorsPortfolio Return Report & Real-Time Buy Signal Notifications - Улправда
Will Intensity Therapeutics Inc. stock split attract more investorsJuly 2025 News Drivers & AI Based Buy and Sell Signals - Улправда
Growth Review: What insider trading reveals about Intensity Therapeutics Inc. stockJuly 2025 Sector Moves & AI Based Trade Execution Alerts - DonanımHaber
Fundamentals Check: Can Intensity Therapeutics Inc. stock double in next 5 yearsWeekly Gains Report & Growth Focused Entry Reports - Улправда
Can Intensity Therapeutics Inc. stock resist sector downturns2025 Earnings Impact & Fast Gain Stock Tips - Улправда
Is Intensity Therapeutics Inc. stock supported by innovation pipelineDip Buying & Daily Volume Surge Trade Alerts - Улправда
Market Review: Why Intensity Therapeutics Inc. stock is a must watch in 2025IPO Watch & Verified Technical Signals - Улправда
MSN Money - MSN
Intensity Therapeutics to present two posters ay SABCS - MSN
All You Need to Know About Intensity Therapeutics Inc. (INTS) Rating Upgrade to Buy - sharewise.com
All you need to know about Intensity Therapeutics Inc. (INTS) rating upgrade to buy - MSN
Immuron (IMRN) struggles after announcing trial results - MSN
Value Recap: Is Intensity Therapeutics Inc stock positioned for digital transformationJuly 2025 Snapshot & Technical Confirmation Trade Alerts - moha.gov.vn
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium - PR Newswire
What drives Intensity Therapeutics Inc stock priceTechnology Stock Trends & Explosive Profit Potential - earlytimes.in
Intensity Therapeutics reports Q3 EPS (6c) vs. (25c) last year - MSN
You might want to take a look at Intensity Therapeutics Inc (INTS) now - setenews.com
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement - marketscreener.com
HC Wainwright & Co. initiates coverage of Pasithea Therapeutics (KTTA) with buy recommendation - MSN
Intensity Therapeutics granted 180-day extension to regain Nasdaq compliance - MSN
INTS Stock Price and Chart — NASDAQ:INTS - TradingView
Update Report: How Intensity Therapeutics Inc stock benefits from global expansionPortfolio Gains Summary & AI Based Trade Execution Alerts - moha.gov.vn
Intensity Therapeutics gets 180-day extension to meet Nasdaq price rule - Investing.com Nigeria
Intensity Therapeutics receives 180-day Nasdaq extension to regain compliance - MSN
Intensity Therapeutics stock rises after securing Nasdaq listing extension By Investing.com - Investing.com Nigeria
Intensity Therapeutics stock rises after securing Nasdaq listing extension - Investing.com
Intensity Therapeutics Gets Extension to Regain Nasdaq Minimum Price Requirement - marketscreener.com
Intensity Therapeutics Granted Nasdaq Compliance Extension - TipRanks
Intensity Therapeutics granted 180-day extension - marketscreener.com
Intensity Therapeutics gets 180-day extension to meet Nasdaq price rule By Investing.com - Investing.com South Africa
Intensity Therapeutics jumps after Nasdaq grants compliance extension - TradingView — Track All Markets
Intensity Therapeutics, Inc. (INTS) 18.98% in Intraday Trading: Surge Ahead of Conference Presentations - Stocks Telegraph
Intensity Therapeutics expands at-the-market offering - MSN
Intensity Therapeutics files for offering of up to $30 million common stockSEC filing - marketscreener.com
Intensity Therapeutics expands at-the-market offering program to $30 million - Investing.com Australia
Intensity Therapeutics announces two presentations at the upcoming 2025 San Antonio Breast Cancer Symposium - marketscreener.com
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium - Nasdaq
Intensity Therapeutics expands at-the-market offering program to $30 million By Investing.com - Investing.com South Africa
Intensity Therapeutics Expands At-The-Market Offering - TipRanks
Intensity Therapeutics Expands ATM Offering to $30 Million - TradingView — Track All Markets
Chipmakers Recap: Why FARO Technologies Inc. stock could see breakout soonWall Street Watch & Momentum Based Trading Signals - BỘ NỘI VỤ
How Intensity Therapeutics Inc. stock benefits from global expansionEarnings Recap Report & Verified Chart Pattern Signals - Newser
Delving into the physics of cancer, with Lew Bender - pharmaphorum
Intensity Therapeutics (INTS) Stock Analysis Report | Financials & Insights - Benzinga
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):